



Available online on 20.06.2019 at <http://jddtonline.info>

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited



Open  Access

Research Article

Formulation Development and Evaluation of Bilayer Tablet for Effective Treatment of Gastric Ulcer

Ajay Rohit, Mukesh Kumar Patel*, Ashish Manigauha

Mittal Institute of Pharmacy, Bhopal (M.P.), India

ABSTRACT

The present study was aimed at developing Gastro retentive bilayer drug delivery systems containing esomeprazole and clarithromycin for the treatment of *H. pylori* induced gastric ulcer to minimize the side effect, improve the prolongation of action, to reduce the frequency of drug administration. The tablet is characterized by immediate release layer of esomeprazole and Gastroretentive layer of clarithromycin. The formulation containing Gastroretentive layer was designed using HPMC K 15, HPMC K 4 and PVP K 30 as floating agents, sodium bicarbonate and citric acid as gas-generating agent. Crospovidone, sodium starch glycolate and croscarmellose sodium was used as superdisintegrant for the preparation of immediate release layer. The prepared Gastroretentive layer was evaluated for their precompression parameters, physical characteristics like hardness, friability, uniformity of weight, uniformity of drug content, swelling index, *In-vitro* floating studies and *In-vitro* drug release. The release of the esomeprazole from the immediate release layer was found to be 89.98 % in 15minutes. The release of clarithromycin for the sustained release floating layer was found to be 98.89±0.47% in 12 hours. The data obtained from *In-vitro* release were fitted into the various kinetic models (Zero Order, Higuchi, First Order and Korsmeyer–Peppas Model).

Keywords: Esomeprazole, Clarithromycin, Bilayer floating tab, Crospovidone, Superdisintegrant

Article Info: Received 05 May 2019; Review Completed 03 June 2019; Accepted 09 June 2019; Available online 20 June 2019



Cite this article as:

Rohit A, Patel MK, Manigauha A, Formulation Development and Evaluation of Bilayer Tablet for Effective Treatment of Gastric Ulcer, Journal of Drug Delivery and Therapeutics. 2019; 9(3-s):705-710 <http://dx.doi.org/10.22270/jddt.v9i3-s.2960>

*Address for Correspondence:

Mukesh Kumar Patel, Mittal Institute of Pharmacy, Bhopal (M.P.) India

INTRODUCTION

Oral route has been the most widely used and most convenient route for the delivery of drugs. Oral route of administration has received more attention than any other dosage form in the pharmaceutical industry and research field because of the flexibility in designing of dosage form and freedom from problems like sterility and potential damage at the site of administration. Approximately 50% of the drug delivery system in the market is oral drug delivery system. Drugs that are rapidly absorbed from the gastrointestinal tract and have a short half life are eliminated quickly from the blood circulation and therefore require frequent dosing. To avoid this problem, the oral sustained release formulation have been developed in an attempt to release the drug slowly into the gastrointestinal tract and maintain the therapeutic drug concentration in the serum for longer period of time. The oral controlled-release system is characterized by a typical pattern of drug release in which the drug concentration is maintained in the therapeutic window for a prolonged period of time, thereby ensuring sustained therapeutic action¹. Peptic ulcer can be defined as any sore in the linings of GIT particularly stomach

or duodenum. There are two most common types of peptic ulcers called “gastric ulcers” and “duodenal ulcers”. Peptic ulcer occurs as a result of imbalance between the aggressive (acid, pepsin, bile and *H. pylori*) and the defensive (gastric mucus and bicarbonate secretion, prostaglandins, nitric oxide, innate resistance of the mucosal cells) factors. *Helicobacter pylori* are an important cause of duodenal and gastric ulcers. Greater than 90% of duodenal ulcers and 70% of gastric ulcers are associated with *H. pylori*. *H. pylori* are a gram-negative, motile, micro-aerophilic, curved bacillus that is found in the mucus layer overlying the gastric epithelium². The treatment for eradication of *H. pylori* is complicated, requiring a combination of an antibiotic with gastric acid inhibitors. Therefore, a well designed drug delivery system is required to overcome the troubles of conventional therapy and to enhance the therapeutic efficacy of given drug regimens. Gastroretentive drug deliveries locate the drug within the stomach and prolong ultimate contact with the absorbing membrane and increases efficacy. This is particularly important in the treatment of microorganisms which colonize in the stomach because the three main fraction reducing luminal delivery of drug to them are gastric emptying, gastric acidity and epithelial mucus layer³. In

particular, H. Pylori lives deep within the gastric mucus layer and prolonged local application is needed for sufficient to diffuse to the bacteria. Esomeprazole an S-isomer of omeprazole that acts as proton pump inhibitor used to treat gastric ulcer. It suppresses acid production by inhibiting gastric parietal H⁺/K⁺ ATPase involved in hydrochloric acid production in the stomach⁴. Clarithromycin is a broad spectrum antimicrobial new generation macrolide active against most Gram positive aerobic cocci and Gram positive bacilli⁵. The activity of clarithromycin is enhanced by its extensive tissue distribution and by formation of the 14-(R)-hydroxylclarithromycin metabolite. Clarithromycin and 14-(R)-hydroxylclarithromycin have a minimum inhibitory concentration of 0.03 and 0.06 µg/ml for h. pylori, respectively. The clarithromycin is reported that it has activity against h pylori bacteria that causes peptic ulcer⁶. The current investigation aims at the development of Gastroretentive Bilayer floating tablets with different release patterns of esomeprazole and clarithromycin. Clarithromycin is an antibiotic to treat H. Pylori and esomeprazole is proton pump inhibitor to reduce gastric acid secretion.

MATERIALS AND METHODS

Esomeprazole and Clarithromycin were gifted by Aurobindo Pharma Limited, Hyderabad A.P, India. HPMC K4M, K15M, PVP K30 was obtained from Mapromax, Life sciences Pvt. Ltd. Dehradun. Sodium bicarbonate, citric acid, magnesium

stearate and talc were obtained from Loba Chemical Pvt Ltd (Mumbai, India). Crospovidone, Sodium starch glycolate, Croscarmellose sodium obtained from Danmed Pharmaceuticals Pvt Ltd, Hyderabad. Hydrochloric acid was obtained from S. D. Fine Chem. Ltd., Mumbai. All other chemical were purchased from Hi Media, Mumbai. Double distilled water was prepared freshly and used whenever required. All other chemicals used in this study including those stated were of analytical reagent (A.R.) grade.

Formulation Development

Formulation of immediate release (IR) layer

Fast dissolving tablets of Esomeprazole were prepared by direct compression method after incorporating different superdisintegrants such as, croscarmellose sodium (Ac-Di-Sol), crospovidone and sodium starch glycolate in different concentrations. All the ingredients given in table 1 were weighed and mixed in geometric progression in a dry and clean mortar. Then the ingredients were passed through mesh #60. The Blend was compressed on 8 mm (diameter) fat punches on a 'Rimek mini press 16 station rotary compression machine. Nine formulations of Esomeprazole granules were prepared and each formulation contained one of the three disintegrate in different concentration. Each tablets weighing 100 mg, were obtained. Composition of tablets is mentioned in Table 1.

Table 1 Composition of esomeprazole fast dissolving tablets

Ingredients(mg)	Formulation code								
	IF1	IF2	IF3	IF4	IF5	IF6	IF7	IF8	IF9
Esomeprazole	40	40	40	40	40	40	40	40	40
Sodium Starch glycolate	10	15	20	-	-	-	-	-	-
Croscarmellose sodium	-	-	-	10	15	20	-	-	-
Crospovidone	-	-	-	-	-	-	10	15	20
Microcrystalline cellulose	39	34	29	39	34	29	39	34	29
Talc	5	5	5	5	5	5	5	5	5
Magnesium stearate	6	6	6	6	6	6	6	6	6
Total weight	100	100	100	100	100	100	100	100	100

Formulation of floating sustained release (SR) layer

Direct compression was followed to manufacture the gas generating floating tablets of Clarithromycin. Nine different formulations (F1, F2, F3, F4, F5, F6, F7, F8, & F9) were

prepared by direct compression. All the polymers selected, drug and excipients were passed through sieve no. 40 before using into formulation. The amount and ratio of drug and polymers were weighed as per given in table 2 and all the formulation were used for further evaluations parameters.

Table 2 Various formulations of clarithromycin gastro retentive tablet

Excipients(mg)	F1	F2	F3	F4	F5	F6	F7	F8	F9
Clarithromycin	250	250	250	250	250	250	250	250	250
HPMC K 15	-	-	-	120	140	160	60	70	80
HPMC K 4	120	140	160	-	-	-	60	70	80
PVP K30	15	15	15	15	15	15	15	15	15
Citric acid	5	5	5	5	5	5	5	5	5
NaHCO ₃	15	15	15	15	15	15	15	15	15
Mg(C ₁₈ H ₃₅ O ₂) ₂	5	5	5	5	5	5	5	5	5
Talc	5	5	5	5	5	5	5	5	5
Lactose	85	65	45	85	65	45	85	65	45
Total Weight	500	500	500	500	500	500	500	500	500

Formulation of bilayer tablet

Optimized formulation IF-6 of Instant release layer (Esomeprazole) and optimized formulation of F-5 (clarithromycin) for control release used for formulation of Bi-layer tablet.

Evaluation of Precompression Parameter

Angle of repose (θ)

The angle of repose was determined by using fixed funnel method. The physical mixtures of drug with different excipients were prepared and the accurately weighed drug powder or its physical mixture was taken in a funnel. The height of the funnel was adjusted in such a way that the tip of the funnel just touches the apex of the heap of the drug powder. The powder was allowed to flow through the funnel freely onto surface. The angle of repose was calculated using the following equation.

$$\theta = \tan^{-1}(h/r)$$

Where, h and r are the height and radius of the powder cone respectively.

Bulk density/tapped density

Both loose bulk density (LBD) and tapped density (TBD) were determined were calculated using the following formulas.

$$\text{LBD} = \text{Powder weight/volume of the packing}$$

$$\text{TBD} = \text{Powder weight /tapped volume of the packing}$$

Compressibility index

The compressibility index of the granules was determined by Carr's compressibility index.

$$\text{Carr's index (\%)} = [(TBD - LBD)/TBD] \times 100.$$

Hausner's ratio

Hausner's ratio is an indirect index of ease of measuring the powder flow. It was calculated by the following formula⁷⁻⁹.

$$\text{Hausner's ratio} = \text{Tapped density/Bulk density.}$$

Evaluation of Post Compression Parameter

Shape and color of tablets

Uncoated tablets were examined under a lens for the shape of the tablet and colour was observed by keeping the tablets in light.

Thickness

Three tablets were picked from each formulation randomly and thickness was measured individually. It is expressed in mm and standard deviation was also calculated. The tablet thickness was measured using dial-caliper (Mitutoyo, Japan).

Hardness

For each formulation, the hardness of five tablets was determined using the Monsanto hardness tester (Cadmach) and measured in terms of kg/cm².

Weight variation

Twenty tablets were selected randomly from each formulation and average weight was determined. The tablets were weighed individually and compared with average weight. The U.S Pharmacopoeia allows a little variation in the weight of a tablet.

Friability

A sample of twenty randomly selected tablets were accurately weighed and placed in a Roche friabilator. The friabilator was operated for 4 min at a speed of 25 rpm. The tablets were removed from the friabilator, de-dusted and reweighed. The percent loss in weight due to abrasion and impact was calculated as,

$$\% \text{Friability} = (\text{Loss in weight/ Initial weight}) \times 100$$

Hardness test

The hardness of tablet was measured by Pfizer hardness tester and results were expressed in Kg/cm².

Uniformity of drug content for IR tablet

The test is mandatory for tablets with 10 mg or less weight of active ingredient. Ten randomly selected tablets from each formulation (F1 to F9) were finely powdered and Drug equivalent to 10 mg of drug dissolved in 10 ml 0.1 N HCl (simulated gastric fluid of pH 1.2 without enzymes) sonicate it for 20 minutes, till the entire drug leached out from complex, then the solution was filtered through whatman filter paper No. 41. From this Solution take 1 ml and Diluted up to 100 ml with 0.1 N HCl and the drug content was determined spectrophotometrically at 282.0nm for Esomeprazole.

Drug content for SR tab

Twenty tablets were taken and amount of drug present in each tablet was determined. The tablets were crushed in a mortar and the powder equivalent to 100mg of drug was transferred to 100ml standard flask. The powder was dissolved in 50 ml of 0.1 N Hcl and made up to volume with of 0.1 N HCl. The sample was mixed thoroughly and filtered through a 0.45 μ membrane filter. The filtered solution was diluted suitably and react with dye and analyzed for drug content by UV spectrophotometer at a λ max of 414.0 nm using of 0.1 N HCL as blank.

Drug content

Twenty tablets were taken and amount of drug present in each tablet was determined. The tablets were crushed in a mortar and the powder equivalent to 25 mg of clarithromycin was transferred to 100ml standard flask. The powder was dissolved in 25 ml of 0.1 N HCL and made up to volume with 0.1 N HCL. The sample was mixed thoroughly and filtered through a 0.45 μ membrane filter. The filtered solution was further diluted 0.1 ml to 10 ml suitably (10 ppm of clarithromycin) and prepares individually 10 ppm solution of Esomeprazole determine the Conc. of both drugs using 282 nm and 416nm for Esomeprazole and clarithromycin respectively.

In vitro buoyancy studies

In vitro buoyancy was determined by floating lag time as per the method described by Rosa *et al*. The tablets were placed separately in a 100 ml glass beaker containing simulated gastric fluid (SGF), pH 1.2 as per USP. The time required for the tablet to rise to the surface and float was determined as floating lag time

Dissolution rate studies of SR tab

In vitro drug release of the sample was carried out using USP- type II dissolution apparatus (Paddle type). The dissolution medium, 900 ml 0.1N HCl was placed into the dissolution flask maintaining the temperature of 37 \pm 0.50c and rpm of 75. One Clarithromycin tablet was placed in each basket of dissolution apparatus. The apparatus was allowed to run for 10 hours. Sample measuring 5 ml were withdrawn

after every 1 hour up to 10 hours using 10ml pipette. The fresh dissolution medium (37°C) was replaced every time with the same quantity of the sample. From this take 0.5 ml and dilute up to 10 ml with 0.1 N HCL, react with dye (methyl orange) and extract with chloroform and take the absorbance at 416.0 nm using spectroscopy.

Dissolution rate studies of Bilayer tab

In vitro drug release was performed according to the USP dissolution apparatus II at 50 rpm and 37±0.5°C temperature over a 12 hrs periods for clarithromycin SR and 1 hr for Esomeprazole IR, using an automated paddle dissolution system (Labindia). A minimum of 6 tablets per

batch were tested. The media used was 0.1N HCL at a pH 1.2 and a volume of 900 ml was maintained at 37±0.5 ° C. Test sample (1ml) was withdrawn at particular time interval and replaced with fresh dissolution media maintained at the same temperature and the concentration of dissolved drug was determined using U.V. (Ultraviolet Labindia 3000+) spectrophotometer at λ_{\max} 282nm for Esomeprazole and 416 nm for clarithromycin respectively.

RESULTS AND DISCUSSIONS

λ_{\max} of Esomeprazole and Clarithromycin was found to be 282 and 416 nm by using U.V. spectrophotometer (Labindia-3000+) Fig.1& 2.




Figure 1 Determination of λ_{\max} of Clarithromycin




Figure 2 Determination of λ_{\max} of Esomeprazole

The powdered blends of different formulations of sustained release floating tablets were evaluated for angle of repose, bulk density (BD), tapped density (TBD) and compressibility index. The results of SR floating tablets are summarized in Table 3. The results of SR floating tablets of BD and TBD ranged from 0.570±0.007 to 0.585±0.003 and 0.728±0.005 to 0.792±0.005 respectively. The range of Hausner ratio and compressibility index was found to be 0.720±0.03 to 0.739±0.03 and 27.30±0.68 to 36.24±0.70 respectively. The results of angle of repose (<35) indicate good flow properties of the powdered blend. The formulation of immediate release tablet prepared by using the superdisintegrants

exhibited the LBD, TBD, angle of repose, compressibility index and Hausner's ratio of within the range, which shows good flow properties of the powdered blend. The prepared tablets were evaluated for different physico-chemical properties and the results are summarized in Table 4 & 5. The tablets were white, circular in shape and were found to be uniform with respect to weight variation, hardness; thickness, friability and content uniformity of different batch of tablets were found within acceptable range and the distribution of drug in all the formulations was uniform. The *in-vitro* drug release of GRF tablets was found in range of 75.63 to 98.89% after 12 hrs table 6.

Table 3 Result of Pre-Compression Properties of Clarithromycin FGR Tablets

Material	Bulk density(gm/ml)	Tapped density(gm/ml)	Compressibility index	Hausner ratio
F1	0.582±0.002	0.732±0.007	27.33±0.73	0.721±0.01
F2	0.581±0.008	0.730±0.006	28.33±0.72	0.723±0.01
F3	0.576±0.002	0.728±0.005	27.30±0.68	0.720±0.01
F4	0.570±0.007	0.729±0.003	29.30±0.65	0.726±0.03
F5	0.580±0.003	0.735±0.004	30.30±0.61	0.730±0.04
F6	0.585±0.003	0.732±0.006	32.80±0.64	0.728±0.06
F7	0.582±0.004	0.742±0.003	36.24±0.70	0.720±0.03
F8	0.579±0.002	0.792±0.005	29.72±0.68	0.720±0.04
F9	0.584±0.004	0.768±0.004	28.52±0.71	0.739±0.03

Table 4 Results of Post-Compression Parameters of Immediate Release

F. Code	Hardness test (kg/cm ²)	Friability (%)	Weight variation (%)	Thickness (mm)	Drug content (%)	In vitro Disintegration Time (sec.) (n=3) Mean ± SD
IF1	3.5	0.485	Passes	2.1	98.56	180±5
IF2	3.6	0.852	Passes	2.2	97.45	120±6
IF3	3.5	0.765	Passes	2.3	98.25	100±8
IF4	3.5	0.898	Passes	2.1	98.12	170±7
IF5	3.3	0.745	Passes	2.1	97.75	100±8
IF6	3.2	0.658	Passes	2.2	98.65	90±4
IF7	3.3	0.458	Passes	2.2	97.45	130±5
IF8	3.4	0.658	Passes	2.3	97.45	140±6
IF9	3.4	0.741	Passes	2.4	98.12	150±7

Table 5 Results of Post Compression Properties of Clarithromycin FGR Tablets

F. code	Thickness (mm)	Hardness (kg/cm ²)	Weight variation (mg)	Friability (%)	Drug content (%)	Total floating duration (h)	Floating lag times (sec)
F1	3.53±0.05	4.8	500.19± 2.94	0.58 ± 0.10	98.33± 0.92	8	28 Sec.
F2	3.94± 0.10	4.4	500.18 ± 3.77	0.51 ± 0.08	97.20 ± 0.34	10	25 Sec.
F3	3.96± 0.05	4.5	500.33 ± 1.50	0.38 ± 0.12	99.60 ± 1.39	>12	33 Sec.
F4	3.95± 0.05	4.7	500.30 ± 3.30	0.16 ± 0.04	98.14 ± 1.69	>12	35 Sec.
F5	3.93± 0.10	5.2	500.13 ± 2.83	0.31 ± 0.07	97.21 ± 1.07	>12	36 Sec.
F6	4.03± 0.06	5.3	500.16 ± 2.33	0.27 ± 0.05	97.50± 1.81	>12	35 Sec.
F7	4.05± 0.05	4.8	500.18 ± 3.11	0.29 ± 0.08	98.34 ± 0.37	>12	31 Sec.
F8	3.98± 0.05	4.5	500.04 ± 2.56	0.34 ± 0.12	98.31± 0.91	>12	30 Sec.
F9	3.69±0.06	4.9	500.02±2.11	0.32±0.09	97.83±0.59	>12	31 Sec.

Table 6 *In-vitro* Drug Release Study of GRF Tablets

Time (hr)	% Cumulative Drug Release								
	F1	F2	F3	F4	F5	F6	F7	F8	F9
0.5	35.65	33.56	30.45	28.89	25.65	22.19	20.15	18.98	12.25
1	45.65	40.12	38.89	35.65	31.45	30.12	25.65	22.32	18.98
1.5	55.69	50.65	48.98	43.14	42.12	38.23	32.13	26.28	25.65
2	69.98	65.56	52.12	49.98	48.23	46.32	47.14	38.21	40.28
3	98.78	89.98	69.98	63.45	61.12	55.56	55.65	45.65	46.65
4	-	99.45	85.65	80.12	75.65	62.12	65.45	55.65	54.45
6	-	-	98.78	91.45	83.12	69.45	73.23	64.45	60.12
8	-	-	-	98.78	88.65	77.89	80.23	70.23	69.12
12	-	-	-	-	98.89	83.23	85.65	78.98	75.63

The prepared bilayer tablets were evaluated for different physico-chemical properties and the results are summarized in Table 7. The tablets were found to be uniform with respect to weight variation and hardness ($5.45 \pm 0.21 \text{ kg/cm}^2$). The thickness ($5.4 \pm 0.2 \text{ mm}$) and friability ($0.725 \pm 0.01\%$) of optimized batch of tablets were found within acceptable range. Content uniformity of formulations was found to be

99.46 %, where the distribution of drug in all the formulations was uniform. The Instant layer of Esomeprazole release Approx 89.98 percent drug within 15 minutes and control floating layer Clarithromycin shows release up to 12 Hours Approx 98.89±0.47 percent. The release of bilayer tablet is shown in Fig.2.

Table 7 Post-Compressional Parameters of Bilayer Tablets

Formulation code	Hardness test (kg/cm^2)	Friability (%)	Weight variation	Thickness (mm)	Drug content
1.	5.45 ± 0.21	0.725 ± 0.01	Passes	5.4 ± 0.2	99.46 ± 0.21




Figure 3 Graph of Release of Bilayer tablets

CONCLUSION

The Experiment relates to formulation and development of oral pharmaceutical bilayer tablet of esomeprazole and clarithromycin for administration of therapeutically and prophylactically effective amount of drug substance to obtain both a relatively fast or quick onset of therapeutic effect and maintenance of a therapeutically active plasma concentration for relatively long period of time. Experiment conclude that Bi-layer tablet is suitable for delivering drugs with different release pattern like one layer of drug as immediate release to get quick relief and second drug as

sustained release of drug which gives effect of drug for sufficient long time and reduce frequency of dose.

REFERENCES

- Joseph RR, Rhodes CT. Modern Pharmaceutics. 3rd edition, Marcel Dekker, Inc., New York. 1996; 58.
- Tripathi KD. Essential of Medical Pharmacology. 6th Edition, Jaypee Brother Medical Publishers (P) Ltd.; 2008;628.
- Jain S, Jain V, Mahajan S C. Design and Characterization of Gastroretentive Bilayer Tablet of Amoxicillin Trihydrate and Ranitidine Hydrochloride for H. pylori Infection. Indian J Pharma Edu Res 2014;48:118-131
- Sean CS. Esomeprazole. In: Sean C.S. Martindale: The Complete Drug Reference. 32nd ed. London: Royal Pharmaceutical Society of Great Britain; 2002.
- Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. Clinical Pharmacokinetics. 1993; 25:189-204.
- Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, DeBartolo ML, Schneck DW. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrobial Agents and Chemotherapy. 1995; 39:2078- 2083.
- Lieberman HA, Lachman L, Schwartz JB. Pharmaceutical dosage forms: Tablets, 3rd edition, Marcel Dekker, New York, 1990.
- Lordi GN. Sustained release dosage forms. In: Lachman L, Lieberman HA, Kanig JL, 3rd edition. The Theory and Practice of Industrial Pharmacy. Mumbai, India: Varghese Publishing House; 1987:430-456;
- Aulton ME; Wells TI; Pharmaceutics: The Science of Dosage Form Design, Churchill Livingstone, London, England, 1988.